title: National consensus on geriatric immunization 2011.
abstract: As the growth of elderly population increases, the number of geriatric patients who may demand health care services is also increasing since the elderly are more vulnerable to various conditions of acute illnesses. Upper respiratory tract infections are the leading cause of death and the most significant cause that impairs quality of life in the elderly. Upper respiratory tract infections and influenza are common in the elderly and may develop into pneumonia.  Considering the high morbidity and mortality rates related to pneumonia in the elderly, it is important to have prevention strategies. A delay in diagnosis due to non-specific signs and symptoms of pneumonia in the elderly has demanded greater concern on the importance of pneumonia prevention strategies. Influenza and pneumonia impair quality of life in the elderly, resulted in decreased functional status (ADL scores) during infection and recovery period. With increasing antibiotic resistance, the management may be complicated as it may lead to conditions that reduce quality of life and cause high mortality rate. Therefore, immunization is very important as the prevention strategy against influenza and or pneumonia, reducing the incidence as well as the complication.  The consensus has been made in order to provide immunization against influenza and pneumonia for elderly population in Indonesia. It is expected that by 2025, about 60% of the elderly in Indonesia would have immunization against influenza and 50% of them would have immunization against pneumonia annually.
authors.affiliation: Department of Internal Medicine, University of Indonesia, Jakarta, Indonesia. geriatric_fkui@yahoo.com
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000075202:Contraindications; D006801:Humans; D007214:Indonesia / Q000453:epidemiology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D011014:Pneumonia / Q000453:epidemiology / Q000517:prevention & control*; D014611:Vaccination / Q000009:adverse effects / Q000379:methods
chemical_list: D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines